Diabetes 51:2817-2825, 2002
© 2002 by the American Diabetes Association, Inc.
Nitrosative Stress, Uric Acid, and Peripheral Nerve Function in Early Type 1 Diabetes
Robert D. Hoeldtke1,
Kimberly D. Bryner1,
Daniel R. McNeill1,
Gerald R. Hobbs2,
Jack E. Riggs3,
Sarah S. Warehime1,
Ian Christie4,
Gary Ganser4, and
Knox Van Dyke5
1 Department of Medicine, West Virginia University (WVU), Morgantown, West Virginia
2 Department of Community Medicine and Statistics, WVU, Morgantown, West Virginia
3 Department of Neurology, WVU, Morgantown, West Virginia
4 Department of Mathematics, WVU, Morgantown, West Virginia
5 Department of Biochemistry and Molecular Pharmacology, WVU, Morgantown, West Virginia
The present study was performed to determine whether nitric oxide overproduction is associated with deterioration in peripheral nerve function in type 1 diabetes. We measured peripheral nerve function and biochemical indicators of nitrosative stress annually for 3 years in 37 patients with type 1 diabetes. Plasma nitrite and nitrate (collectively NOx) were 34.0 ± 4.9 µmol/l in the control subjects and 52.4 ± 5.1, 50.0 ± 5.1, and 49.0 ± 5.2 in the diabetic patients at the first, second, and third evaluations, respectively (P < 0.01). Nitrotyrosine (NTY) was 13.3 ± 2.0 µmol/l in the control subjects and 26.8 ± 4.4, 26.1 ± 4.3, and 32.7 ± 4.3 in the diabetic patients (P < 0.01). Uric acid was suppressed by 20% in the diabetic patients (P < 0.001). Composite motor nerve conduction velocity for the median, ulnar, and peroneal nerves was decreased in patients with high versus low NTY (mean Z score -0.522 ± 0.25 versus 0.273 ± 0.22; P < 0.025). Patients with high NOx had decreased sweating, and those with suppressed uric acid had decreased autonomic function. In conclusion, nitrosative stress in early diabetes is associated with suppressed uric acid and deterioration in peripheral nerve function.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
Related Article:
-
Retraction
- Franz M. Matschinsky
Diabetes 2006 55: 2664.
[Extract]
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
P. Pacher and C. Szabo
Role of the Peroxynitrite-Poly(ADP-Ribose) Polymerase Pathway in Human Disease
Am. J. Pathol.,
July 1, 2008;
173(1):
2 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Pacher, J. S. Beckman, and L. Liaudet
Nitric Oxide and Peroxynitrite in Health and Disease
Physiol Rev,
January 1, 2007;
87(1):
315 - 424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. M. Matschinsky
Retraction
Diabetes,
September 1, 2006;
55(9):
2664 - 2664.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. I. Vinik, J. Ullal, H. K. Parson, P. M. Barlow, and C. M. Casellini
Pioglitazone Treatment Improves Nitrosative Stress in Type 2 Diabetes
Diabetes Care,
April 1, 2006;
29(4):
869 - 876.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ziegler, C. G.H. Sohr, and J. Nourooz-Zadeh
Oxidative Stress and Antioxidant Defense in Relation to the Severity of Diabetic Polyneuropathy and Cardiovascular Autonomic Neuropathy
Diabetes Care,
September 1, 2004;
27(9):
2178 - 2183.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. G. Obrosova, F. Li, O. I. Abatan, M. A. Forsell, K. Komjati, P. Pacher, C. Szabo, and M. J. Stevens
Role of Poly(ADP-Ribose) Polymerase Activation in Diabetic Neuropathy
Diabetes,
March 1, 2004;
53(3):
711 - 720.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. I. Vinik, R. E. Maser, B. D. Mitchell, and R. Freeman
Diabetic Autonomic Neuropathy
Diabetes Care,
May 1, 2003;
26(5):
1553 - 1579.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Hoeldtke, K. D. Bryner, D. R. McNeill, S. S. Warehime, K. Van Dyke, and G. Hobbs
Oxidative Stress and Insulin Requirements in Patients with Recent-Onset Type 1 Diabetes
J. Clin. Endocrinol. Metab.,
April 1, 2003;
88(4):
1624 - 1628.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Diabetes Association.
|
|
| |
|